View in EDS

Placebo-controlled trial of moclobemide in social phobia.

Saved in:
Bibliographic Details
Title: Placebo-controlled trial of moclobemide in social phobia.
Authors: Schneier, Franklin R., Goetz, Deborah, Campeas, Raphael, Fallon, Brian, Marshall, Randall, Liebowitz, Michael R., Schneier, F R (AUTHOR), Goetz, D (AUTHOR), Campeas, R (AUTHOR), Fallon, B (AUTHOR), Marshall, R (AUTHOR), Liebowitz, M R (AUTHOR)
Source: British Journal of Psychiatry. Jan98, Vol. 172, p70-77. 8p. 4 Charts.
Subjects: Placebos, Antidepressants, Clinical medicine research, Medical research, Clinical trials, Mental health services, Mental health, Pathological psychology, Psychoses, Psychiatry
Abstract: Background: Moclobemide, a reversible inhibitor of monoamine oxidase A, previously has been reported to have efficacy in the treatment of social phobia.Method: Seventy-seven non-responders to one week of single-blind placebo were randomly assigned to moclobemide or placebo for eight weeks of double-blind treatment. Outcome was assessed by independent evaluator, treating psychiatrist and self-ratings. After eight weeks, patients who were at least minimally improved continued treatment for a further eight weeks.Results: Intention-to-treat sample response rates at week 8 were 7/40 (17.5%) for the moclobemide group and 5/37 (13.5%) for placebo (NS). Moclobemide was significantly superior to placebo on 2 of 10 primary outcome measures. Moclobemide was well tolerated.Conclusions: Moclobemide may have efficacy in the treatment of social phobia, but absence of significant differences on most primary outcome measures and small effect sizes for all outcome measures suggest that the magnitude of its clinical effect is small. [ABSTRACT FROM AUTHOR]
Copyright of British Journal of Psychiatry is the property of Cambridge University Press and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 24938976
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Placebo-controlled trial of moclobemide in social phobia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Schneier%2C+Franklin+R%2E%22">Schneier, Franklin R.</searchLink><br /><searchLink fieldCode="AR" term="%22Goetz%2C+Deborah%22">Goetz, Deborah</searchLink><br /><searchLink fieldCode="AR" term="%22Campeas%2C+Raphael%22">Campeas, Raphael</searchLink><br /><searchLink fieldCode="AR" term="%22Fallon%2C+Brian%22">Fallon, Brian</searchLink><br /><searchLink fieldCode="AR" term="%22Marshall%2C+Randall%22">Marshall, Randall</searchLink><br /><searchLink fieldCode="AR" term="%22Liebowitz%2C+Michael+R%2E%22">Liebowitz, Michael R.</searchLink><br /><searchLink fieldCode="AR" term="%22Schneier%2C+F+R%22">Schneier, F R</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Goetz%2C+D%22">Goetz, D</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Campeas%2C+R%22">Campeas, R</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fallon%2C+B%22">Fallon, B</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Marshall%2C+R%22">Marshall, R</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Liebowitz%2C+M+R%22">Liebowitz, M R</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22British+Journal+of+Psychiatry%22">British Journal of Psychiatry</searchLink>. Jan98, Vol. 172, p70-77. 8p. 4 Charts.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Placebos%22">Placebos</searchLink><br /><searchLink fieldCode="DE" term="%22Antidepressants%22">Antidepressants</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+medicine+research%22">Clinical medicine research</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+research%22">Medical research</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+trials%22">Clinical trials</searchLink><br /><searchLink fieldCode="DE" term="%22Mental+health+services%22">Mental health services</searchLink><br /><searchLink fieldCode="DE" term="%22Mental+health%22">Mental health</searchLink><br /><searchLink fieldCode="DE" term="%22Pathological+psychology%22">Pathological psychology</searchLink><br /><searchLink fieldCode="DE" term="%22Psychoses%22">Psychoses</searchLink><br /><searchLink fieldCode="DE" term="%22Psychiatry%22">Psychiatry</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>Moclobemide, a reversible inhibitor of monoamine oxidase A, previously has been reported to have efficacy in the treatment of social phobia.<bold>Method: </bold>Seventy-seven non-responders to one week of single-blind placebo were randomly assigned to moclobemide or placebo for eight weeks of double-blind treatment. Outcome was assessed by independent evaluator, treating psychiatrist and self-ratings. After eight weeks, patients who were at least minimally improved continued treatment for a further eight weeks.<bold>Results: </bold>Intention-to-treat sample response rates at week 8 were 7/40 (17.5%) for the moclobemide group and 5/37 (13.5%) for placebo (NS). Moclobemide was significantly superior to placebo on 2 of 10 primary outcome measures. Moclobemide was well tolerated.<bold>Conclusions: </bold>Moclobemide may have efficacy in the treatment of social phobia, but absence of significant differences on most primary outcome measures and small effect sizes for all outcome measures suggest that the magnitude of its clinical effect is small. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of British Journal of Psychiatry is the property of Cambridge University Press and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=24938976
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1192/bjp.172.1.70
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 8
        StartPage: 70
    Subjects:
      – SubjectFull: Placebos
        Type: general
      – SubjectFull: Antidepressants
        Type: general
      – SubjectFull: Clinical medicine research
        Type: general
      – SubjectFull: Medical research
        Type: general
      – SubjectFull: Clinical trials
        Type: general
      – SubjectFull: Mental health services
        Type: general
      – SubjectFull: Mental health
        Type: general
      – SubjectFull: Pathological psychology
        Type: general
      – SubjectFull: Psychoses
        Type: general
      – SubjectFull: Psychiatry
        Type: general
    Titles:
      – TitleFull: Placebo-controlled trial of moclobemide in social phobia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Schneier, Franklin R.
      – PersonEntity:
          Name:
            NameFull: Goetz, Deborah
      – PersonEntity:
          Name:
            NameFull: Campeas, Raphael
      – PersonEntity:
          Name:
            NameFull: Fallon, Brian
      – PersonEntity:
          Name:
            NameFull: Marshall, Randall
      – PersonEntity:
          Name:
            NameFull: Liebowitz, Michael R.
      – PersonEntity:
          Name:
            NameFull: Schneier, F R
      – PersonEntity:
          Name:
            NameFull: Goetz, D
      – PersonEntity:
          Name:
            NameFull: Campeas, R
      – PersonEntity:
          Name:
            NameFull: Fallon, B
      – PersonEntity:
          Name:
            NameFull: Marshall, R
      – PersonEntity:
          Name:
            NameFull: Liebowitz, M R
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: Jan98
              Type: published
              Y: 1998
          Identifiers:
            – Type: issn-print
              Value: 00071250
          Numbering:
            – Type: volume
              Value: 172
          Titles:
            – TitleFull: British Journal of Psychiatry
              Type: main
ResultId 1